IL-1β and Allergy: Focusing on Its Role in Allergic Rhinitis

Wang HR, Wei SZ, Song XY, Wang Y, Zhang WB, Ren C, Mou YK, Song XC. Mediators Inflamm. 2023 Apr 12;2023:1265449. doi: 10.1155/2023/1265449.

Abstract

Allergic rhinitis (AR) is a chronic upper airway immune-inflammation response mediated by immunoglobulin E (IgE) to allergens and can seriously affect the quality of life and work efficiency. Previous studies have shown that interleukin-1β (IL-1β) acts as a key cytokine to participate in and promote the occurrence and development of allergic diseases.

High baseline prevalence of atopic comorbidities and medication use in children treated with allergy immunotherapy in the REAl-world effeCtiveness in allergy immunoTherapy (REACT) study

Fritszching B, Porsbjerg C, Buchs S, Larsen JR, Freemantle N, Contoli M. H Front Pediatr. 2023 Mar 28;11:1136942. doi: 10.3389/fped.2023.1136942. 

Abstract

Background: Respiratory allergy, commonly manifesting as allergic rhinitis (AR) and asthma, is a chronic progressive disease that frequently starts in childhood. Allergy immunotherapy (AIT) is the only causal treatment for respiratory allergy with the potential to modify the underlying cause of allergy and, ultimately, prevent disease progression. This analysis aimed to determine if AIT is received sufficiently early to halt the progression of allergic disease, by characterizing the burden and progression of disease in children prior to AIT initiation in real-life clinical practice.

Methods: The REAl-world effeCtiveness in allergy immunoTherapy (REACT) study was a large retrospective cohort study using German claims data between 2007 and 2017. Characteristics of two pre-defined AIT age cohorts from the REACT study - children (aged <18 years) and adults (aged ≥18 years) - were evaluated during the 1-year period before the first AIT prescription.

Consensus on the management of united airways disease with type 2 inflammation: a multidisciplinary Delphi study

• Research
• Open Access
• 
  

• Marina Blanco-Aparicio, 
• Javier Domínguez-Ortega, 
• Carolina Cisneros, 
• Carlos Colás, 
• Francisco Casas, 
• Alfonso del Cuvillo, 
• Isam Alobid, 
• Santiago Quirce & 
• Joaquim Mullol 

Allergy, Asthma & Clinical Immunology volume 19, Article number: 34 (2023) 

Abstract

Background

Scientific evidence on patients with multimorbid type 2 asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) from a united airways disease (UAD) perspective remains scarce, despite the frequent coexistence of these entities. We aimed to generate expert consensus-based recommendations for the management of UAD patients.

Methods

Using a two-round Delphi method, Spanish expert allergists, pulmonologists and otolaryngologists expressed their agreement on 32 statements (52 items) on a 9-point Likert scale, classified as appropriate (median 7–9), uncertain (4–6) or inappropriate (1–3). Consensus was considered when at least two-thirds of the panel scored within the range containing the median.

Penicillin de-labelling in vancouver, British Columbia, Canada: comparison of approaches, outcomes and future directions

Sujen Saravanabavan, 

Amneet Aulakh, 

Josh Douglas, 

Chelsea Elwood, 

Stephanie Erdle, 

Jennifer Grant, 

Kristopher T. Kang, 

Natasha Kwan, 

Katie Lacaria, 

Tim T. Y. Lau, 

Colin Lee, 

Victor Leung, 

Yu-Chen Lin, 

Allison Mah, 

Anne Nguyen, 

Vanessa Paquette, 

Ashley Roberts, 

Melissa Watt, 

Julie Van Schalkwyk, 

Bei Yuan Zhang, 

Raymond Mak & 

Tiffany Wong 

Allergy, Asthma & Clinical Immunology volume 19, Article number: 30 (2023) 

• details

Abstract

Background

Inaccurate penicillin allergy labels lead to inappropriate antibiotic prescriptions and harmful patient consequences. System-wide efforts are needed to remove incorrect penicillin allergy labels, but more health services research is required on how to best deliver these services.

Methods

Data was extracted from five hospitals in Vancouver, British Columbia, Canada from October 2018-May 2022. The primary outcomes of this study were to outline de-labelling protocol designs, identify the roles of various healthcare professionals in de-labelling protocols and identify rates of de-labelling penicillin allergies and associated adverse events at various institutions.

Prenatal and early-life exposure to traffic-related air pollution and allergic rhinitis in children: A systematic literature review

Lifang Liu, Jingxuan Ma, Shanshan Peng, Linshen Xie 

PLoS One. 2023 Apr 20;18(4):e0284625. doi: 10.1371/journal.pone.0284625.

Abstract

Background

Traffic-related air pollution (TRAP) is hypothesised to play a role in the development of allergic rhinitis (AR). Prenatal and early-life exposure to traffic-related air pollution is considered critical for later respiratory health. However, we could not find any articles systematically reviewing the risk of prenatal and early-life exposure to traffic-related air pollution for allergic rhinitis in children.

Long term longitudinal follow-up of an AD-HIES cohort: the impact of early diagnosis and enrollment to IPINet centers on the natural history of Job’s syndrome

• Research
• Open Access
• 
  

• Maria Carrabba, 
• Rosa Maria Dellepiane, 
• Manuela Cortesi, 
• Lucia Augusta Baselli, 
• Annarosa Soresina, 
• Emilia Cirillo, 
• Giuliana Giardino, 
• Francesca Conti, 
• Laura Dotta, 
• Andrea Finocchi, 
• Caterina Cancrini, 
• Cinzia Milito, 
• Lucia Pacillo, 
• Bianca Laura Cinicola, 
• Fausto Cossu, 
• Rita Consolini, 
• Davide Montin, 
• Isabella Quinti, 
• Andrea Pession, 
• Giovanna Fabio, 
• Claudio Pignata, 
• Maria Cristina Pietrogrande & 
• Raffaele Badolato 

Allergy, Asthma & Clinical Immunology volume 19, Article number: 32 (2023) 

Abstract

Job’s syndrome, or autosomal dominant hyperimmunoglobulin E syndrome (AD-HIES, STAT3-Dominant Negative), is a rare inborn error of immunity (IEI) with multi-organ involvement and long-life post-infective damage. Longitudinal registries are of primary importance in improving our knowledge of the natural history and management of these rare disorders.

This study aimed to describe the natural history of 30 Italian patients with AD-HIES recorded in the Italian network for primary immunodeficiency (IPINet) registry. This study shows the incidence of manifestations present at the time of diagnosis versus those that arose during follow up at a referral center for IEI.

Diagnostic performance of eNose technology in COVID-19 patients after hospitalization

• Research
• Open Access
• 
  

B. F.M. van Raaij, 

J. D. Veltman, 

J. F. Hameete, 

J. L. Stöger & 

J. J.M. Geelhoed 

BMC Pulmonary Medicine volume 23, Article number: 134 (2023) 

• details

Abstract

Background

Volatile organic compounds (VOCs) produced by human cells reflect metabolic and pathophysiological processes which can be detected with the use of electronic nose (eNose) technology. Analysis of exhaled breath may potentially play an important role in diagnosing COVID-19 and stratification of patients based on pulmonary function or chest CT.

Methods

Breath profiles of COVID-19 patients were collected with an eNose device (SpiroNose) 3 months after discharge from the Leiden University Medical Centre and matched with breath profiles from healthy individuals for analysis. Principal component analysis was performed with leave-one-out cross validation and visualised with receiver operating characteristics.

Patient-centred digital biomarkers for allergic respiratory diseases and asthma: the ARIA-EAACI approach

Bousquet J, Shamji MH, Anto JM, et al.  Allergy. 2023 Apr 11. doi: 10.1111/all.15740.

Abstract

Biomarkers for the diagnosis, treatment and follow-up of patients with rhinitis and/or asthma are urgently needed. Although some biologic biomarkers exist in specialist care for asthma, they cannot be largely used in primary care. There are no validated biomarkers in rhinitis or allergen immunotherapy (AIT) that can be used in clinical practice. The digital transformation of health and health care (including mHealth) places the patient at the centre of the health system and is likely to optimise the practice of allergy. ARIA (Allergic Rhinitis and its Impact on Asthma) and EAACI (European Academy of Allergy and Clinical Immunology) developed a Task Force aimed at proposing patient-reported outcome measures (PROMs) as digital biomarkers that can be easily used for different purposes in rhinitis and asthma.